FI882668A - Ex vivo-aktivering av effekterceller foer doedande av objektceller. - Google Patents

Ex vivo-aktivering av effekterceller foer doedande av objektceller. Download PDF

Info

Publication number
FI882668A
FI882668A FI882668A FI882668A FI882668A FI 882668 A FI882668 A FI 882668A FI 882668 A FI882668 A FI 882668A FI 882668 A FI882668 A FI 882668A FI 882668 A FI882668 A FI 882668A
Authority
FI
Finland
Prior art keywords
objektceller
effekterceller
doedande
foer
vivo
Prior art date
Application number
FI882668A
Other languages
English (en)
Finnish (fi)
Other versions
FI882668A0 (fi
Inventor
Cyril J Honsik
Ralph A Reisfeld
Original Assignee
Scripps Clinic Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Clinic Res filed Critical Scripps Clinic Res
Publication of FI882668A0 publication Critical patent/FI882668A0/fi
Publication of FI882668A publication Critical patent/FI882668A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/804—Drug, bio-affecting and body treating compositions involving IgG3, IgG4, IgA, or IgY
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI882668A 1986-10-07 1988-06-06 Ex vivo-aktivering av effekterceller foer doedande av objektceller. FI882668A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/916,173 US4844893A (en) 1986-10-07 1986-10-07 EX vivo effector cell activation for target cell killing
PCT/US1987/002520 WO1988002773A1 (en) 1986-10-07 1987-10-01 Ex vivo effector cell activation for target cell killing

Publications (2)

Publication Number Publication Date
FI882668A0 FI882668A0 (fi) 1988-06-06
FI882668A true FI882668A (fi) 1988-06-06

Family

ID=25436818

Family Applications (1)

Application Number Title Priority Date Filing Date
FI882668A FI882668A (fi) 1986-10-07 1988-06-06 Ex vivo-aktivering av effekterceller foer doedande av objektceller.

Country Status (8)

Country Link
US (1) US4844893A (da)
EP (1) EP0287615A4 (da)
JP (1) JPH01501388A (da)
AU (1) AU605516B2 (da)
CA (1) CA1302324C (da)
DK (1) DK274688A (da)
FI (1) FI882668A (da)
WO (1) WO1988002773A1 (da)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308626A (en) * 1985-06-28 1994-05-03 Toni N. Mariani Lymphokine activated effector cells for antibody-dependent cellular cytotoxicity (ADCC) treatment of cancer and other diseases
US5104652A (en) * 1986-11-13 1992-04-14 Sloan-Kettering Institute For Cancer Research Compositions and method for treatment of cancer using monoclonal antibody against GD3 ganglioside together with IL-2
JP2706777B2 (ja) * 1988-02-19 1998-01-28 メクト株式会社 非天然型ｇｄ▲下３▼を認識するモノクローナル抗体
US4925648A (en) * 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
AU4485089A (en) * 1988-10-21 1990-05-14 Brigham And Women's Hospital Activation and growth of human tumor-infiltrating lymphocytes using antibodies to cd3 or tcr
US5108760A (en) * 1989-07-21 1992-04-28 Terumo Corporation Enhances lak cell activation by treatment of human peripheral blood mononuclear cells with amino acid amides
US5585362A (en) * 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5863770A (en) * 1989-08-22 1999-01-26 Hsc Research And Development Limited Partnership Stable meterologous propagation of CFTR protein variant cDNA
US5240846A (en) * 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
US5543399A (en) * 1989-08-22 1996-08-06 Hsc Research & Development Limited Partnership Cystic fibrosis transmembrane conductance regulator (CFTR) protein
US6984487B1 (en) * 1989-08-22 2006-01-10 Hsc Research Development Corporation Cystic fibrosis gene
US6063913A (en) * 1989-08-22 2000-05-16 Hsc Research And Development Limited Partnership Stable heterologous propagation CFTR protein variant cDNA
WO1991010734A1 (en) * 1990-01-12 1991-07-25 Hsc Research Development Corporation Introns and exons of the cystic fibrosis gene and mutations at various positions of the gene
WO1992010198A1 (en) * 1990-12-06 1992-06-25 Johnson & Johnson Research Pty Limited Immunotherapeutic agents, compositions and methods
US5212075A (en) * 1991-04-15 1993-05-18 The Regents Of The University Of California Compositions and methods for introducing effectors to pathogens and cells
US5364612A (en) * 1991-05-06 1994-11-15 Immunomedics, Inc. Detection of cardiovascular lesions
WO1993005658A1 (en) * 1991-09-25 1993-04-01 The General Hospital Corporation Targeted cytotoxic effector cells and methods for their production and use
US5807549A (en) * 1993-05-21 1998-09-15 Research Corporation Technologies, Inc. Lymphocyte chemoattractant factor and uses thereof
US5674694A (en) * 1993-09-21 1997-10-07 Biologic & Immunologic Science Laboratories, Inc. Clonogenic assay for detecting micro levels of tumor cells in hematopoietic samples
WO1997026328A1 (en) 1996-01-17 1997-07-24 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US6805869B2 (en) 1996-06-12 2004-10-19 Shanghai Cp Guojian Pharmaceutical Co., Ltd. Cellular vaccines and immunotherapeutics and methods for their preparation
EP0956046A4 (en) * 1996-06-12 2004-10-20 Yajun Guo CELLULAR VACCINALS AND IMMUNOTHERAPEUTICS AND METHOD FOR THE PRODUCTION THEREOF
US20050136066A1 (en) * 1996-06-12 2005-06-23 Yajun Guo Cellular vaccines and immunotherapeutics and methods for their preparation
DE19725586C2 (de) * 1997-06-17 1999-06-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper
AU4577899A (en) 1998-06-17 2000-01-05 Epimmune, Inc. Hla binding peptides and their uses
US7541184B2 (en) * 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) * 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
AU2001298049A1 (en) 2000-10-19 2003-05-19 Epimmune Inc. Hla class i and ii binding peptides and their uses
WO2002044207A1 (en) * 2000-11-30 2002-06-06 Imperial College Innovations Limited Immunotherapeutic methods and molecules
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
EP1356048A2 (en) 2000-12-04 2003-10-29 Argonex Pharmaceuticals Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20040236514A1 (en) * 2001-12-13 2004-11-25 Lee Stephen C. Controlling distribution of epitopes in polypeptide sequences
US20040132173A1 (en) * 2002-08-28 2004-07-08 Kimon Angelides Optical fiber array device capable of simultaneously performing multiple functional assays
DE10242146A1 (de) * 2002-09-04 2004-03-18 Eberhard-Karls-Universität Tübingen Universitätsklinikum Antikörper zur Identifizierung und/oder Isolierung von hämatopoetischen Stammzellen
BRPI0317376B8 (pt) * 2002-12-17 2021-05-25 Merck Patent Gmbh proteína de fusão de anticorpo-il2 designada como hu14.18-il2, usos da mesma, vetor e composição farmacêutica
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
EP1697399B1 (en) 2003-12-12 2016-11-23 GOVERNMENT OF THE UNITED STATES OF AMERICA, as repr. by THE SECR. OF THE DEPT. OF HEALTH AND HUMAN SERVICES AND HIS SUCCESSORS A human cytotoxic t-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of muc-1
US20070248628A1 (en) * 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
BRPI0708446A2 (pt) * 2006-03-01 2011-06-07 Janssen Pharmaceutica Nv tratamento de cáncer combinando agente de linfodepleção com ctls e citocinas
US20080107668A1 (en) * 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US8129184B2 (en) 2006-09-26 2012-03-06 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
WO2008039974A2 (en) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
US8124408B2 (en) 2006-10-04 2012-02-28 Janssen Pharmaceutica N.V. Preparation of inactivated artificial antigen presenting cells and their use in cell therapies
EP2328923B1 (en) 2008-09-02 2016-01-13 Cedars-Sinai Medical Center Cd133 epitopes
US9207242B2 (en) * 2008-10-09 2015-12-08 The University Of Hong Kong Cadherin-17 as diagnostic marker and therapeutic target for liver cancer
PL2427485T3 (pl) 2009-05-07 2017-10-31 Immunocellular Therapeutics Ltd Epitopy CD133
EP2470200B1 (en) 2009-08-26 2017-03-15 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US8075895B2 (en) * 2009-09-22 2011-12-13 Janssen Pharmaceutica N.V. Identification of antigenic peptides from multiple myeloma cells
US9694128B1 (en) 2010-02-24 2017-07-04 Brian LeBerthon Device and method for administering an anti-cancer substance
CN103180730B (zh) 2010-05-14 2016-03-02 综合医院公司 鉴定肿瘤特异性新抗原的组合物和方法
WO2013003579A1 (en) 2011-06-29 2013-01-03 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of dengue virus infection
EP2755679B1 (en) 2011-09-13 2017-08-02 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2013049856A2 (en) 2011-09-30 2013-04-04 Hare Joshue M Renal stem cells isolated from kidney
US10137182B2 (en) 2013-02-14 2018-11-27 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods
US9227005B2 (en) 2013-03-14 2016-01-05 Brian J LeBerthon Method and device for treating cancer
WO2014168874A2 (en) 2013-04-07 2014-10-16 The Broad Institute, Inc. Compositions and methods for personalized neoplasia vaccines
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
KR20230076867A (ko) 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
US10155036B2 (en) 2014-02-28 2018-12-18 Emergex Vaccines Holding Ltd. MHC class I associated peptides for prevention and treatment of hepatitis B virus infection
CN106459914B (zh) 2014-05-15 2020-11-06 新加坡国立大学 经修饰的自然杀伤细胞及其用途
WO2016100977A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Methods for profiling the t-cel- receptor repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
MX2017014700A (es) 2015-05-20 2018-08-15 Broad Inst Inc Neoantigenos compartidos.
TWI750122B (zh) 2015-06-09 2021-12-21 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
WO2017075478A2 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
WO2017184590A1 (en) 2016-04-18 2017-10-26 The Broad Institute Inc. Improved hla epitope prediction
WO2018049025A2 (en) 2016-09-07 2018-03-15 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
BR112019019917A2 (pt) 2017-03-27 2020-04-22 Nat Univ Singapore receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais
CN110494557A (zh) 2017-03-27 2019-11-22 新加坡国立大学 用于离体扩增和活化自然杀伤细胞的刺激细胞系
WO2020051766A1 (zh) 2018-09-11 2020-03-19 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
SG11202109057XA (en) 2019-03-05 2021-09-29 Nkarta Inc Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
WO2022047419A1 (en) 2020-08-31 2022-03-03 City Of Hope Novel cell lines, methods of producing natural killer cells and uses thereof
WO2022074098A1 (en) 2020-10-08 2022-04-14 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Method for the identification of cancer neoantigens

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444878A (en) * 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
US4507391A (en) * 1982-04-02 1985-03-26 Sloan-Kettering Institute For Cancer Research Method for detecting the presence of GD3 ganglioside
US4675287A (en) * 1984-07-26 1987-06-23 Scripps Clinic And Research Foundation Monoclonal antibody directed to human ganglioside GD2
US4785077A (en) * 1986-05-05 1988-11-15 Scripps Clinic And Research Foundation Substantially pure cytotoxicity triggering factor
WO1988002117A1 (en) * 1986-09-19 1988-03-24 Scripps Clinic And Research Foundation Monoclonal paratopic molecule directed to human ganglioside gd2

Also Published As

Publication number Publication date
US4844893A (en) 1989-07-04
JPH01501388A (ja) 1989-05-18
FI882668A0 (fi) 1988-06-06
DK274688D0 (da) 1988-05-19
AU605516B2 (en) 1991-01-17
DK274688A (da) 1988-08-04
EP0287615A4 (en) 1990-02-22
AU8108987A (en) 1988-05-06
CA1302324C (en) 1992-06-02
EP0287615A1 (en) 1988-10-26
WO1988002773A1 (en) 1988-04-21

Similar Documents

Publication Publication Date Title
FI882668A0 (fi) Ex vivo-aktivering av effekterceller foer doedande av objektceller.
FI77063B (fi) Foerfarande foer effektivering av fibersuspensionstvaett.
FI860502A0 (fi) Anordning foer skaerpning av knivar.
FI82029B (fi) Anordning foer vaermehaerdning av glasskivor.
FI860245A0 (fi) Foerfarande foer identifiering av en traeytas ytegenskaper.
FI860623A0 (fi) Foerfarande foer framstaellning av fiskfoderpellets.
FI861457A (fi) Foerfarande foer framstaellning av roerformiga flerskiktade extrusionsprodukter.
FI860379A0 (fi) Foerfarande foer framstaellning av ytbelaeggning.
FI860984A0 (fi) Koppling foer skyddning av mekanism.
FI861027A0 (fi) Anordning foer skyddande av elkomponent.
FI860592A0 (fi) Anordning foer dosering av vaetska.
FI77953B (fi) Koppling foer en likspaenningskaella av resonanstyp.
FI861427A0 (fi) Foerfarande foer tillverkning av transportbana.
FI860217A0 (fi) Verktyg foer framstaellning av kraghaol.
FI860069A (fi) Anordning foer avkylning av vaetska.
FI860071A (fi) Lyftanordning foer installering av vertikalelement.
FI864591A0 (fi) Anordning foer anvaendning av dator.
FI860129A (fi) Anordning foer faestande av sidoplogs vaendskiva.
FI861278A0 (fi) Styckevis avgivare av saogvara.
FI860144A0 (fi) Foerfarande foer framstaellning av fiskfoderpellets.
FI860553A0 (fi) Foerfarande foer sanering av kloakbrunnar.
FI861170A0 (fi) Foerfarande foer laegebestaemning av telemetersaendarna.
FI860183A (fi) Foerfarande foer straolbehandling av laonga flexibla foeremaol.
FI861097A0 (fi) Foerfarande foer alstring av tryck.
FI861051A0 (fi) Hjaelpanordning foer bindning av blommor.

Legal Events

Date Code Title Description
FD Application lapsed
FD Application lapsed

Owner name: SCRIPPS CLINIC AND RESEARCH FOUNDATION